News

Filter

Current filters:

None

37 to 46 of 98149 results

Semma Therapeutics secures $44 million funding to develop diabetes cell therapy

25-03-2015

USA-based biotech start-up Semma Therapeutics, which is developing a cell therapy for type 1 diabetes,…

BiotechnologyDiabetesFinancialNovartisResearchSemma Therapeutics

Lpath's Asonep fails to meet primary endpoint at Phase IIa; shares slide

Lpath's Asonep fails to meet primary endpoint at Phase IIa; shares slide

25-03-2015

Lpath says that its investigational therapy Asonep (sonepcizumab) did not meet the primary endpoint in…

AsonepBiotechnologyLpathOncologyResearch

European Commission approves Santen Pharma’s Ikervis for eye disease

25-03-2015

Japanese drugmaker Santen Pharmaceutical has received approval of the Marketing Authorization Application…

EuropeIkervisOphthalmicsPharmaceuticalRegulationSanten Pharmaceuticals

AstraZeneca collaborates with Harvard Stem Cell Institute on beta cells

AstraZeneca collaborates with Harvard Stem Cell Institute on beta cells

25-03-2015

Anglo-Swedish drug major AstraZeneca has entered into a five-year research collaboration with the Harvard…

AstraZenecaDiabetesPharmaceuticalResearchSweden

Lack of data and data management hindering hepatitis C progress in England, says IMS Health

Lack of data and data management hindering hepatitis C progress in England, says IMS Health

24-03-2015

Limited data and the disparate nature of the datasets that are available have been challenges to measuring…

Markets & MarketingNephrology and HepatologyPharmaceuticalSocial IssuesUK

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

24-03-2015

US pharma major Bristol-Myers Squibb has agreed to acquire from Danish diabetes care giant Novo Nordisk…

BiotechnologyBristol-Myers SquibbGlobalImmunologicalsLicensingNovo Nordisk

Merck halts Keytruda study on positive results in melanoma

24-03-2015

US pharma giant Merck & Co says it will discontinue a study of its cancer drug Keytruda (pembrolizumab)…

BiotechnologyKeytrudaMerck & CoOncologyResearch

New enzalutamide presented by Astellas and Medivation at EAU

24-03-2015

Japanese pharma major Astellas Pharma and US drugmaker Medivation have presented new data from the Phase…

Astellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchXtandi

37 to 46 of 98149 results

Back to top